NEURO-ONCOLOGY • NOVEMBER 2016 combination with TMZ in recurrent refractory malignant brain tumors. METHODS: After progression on TMZ, patients are eligible for enrollment in this study of indoximod (1200 mg twice daily orally) combined with a standard fixed dose of TMZ (150mg/m2 x 5 days). INTRODUCTION: Glioblastoma (GBM) is the most common malignant brain tumor with a median survival of 15 months despite surgery and aggressive radio-chemotherapy. The most important mechanism of TMZ resistance is the O6-methylguanine-DNA methyltransferase (MGMT) gene which repairs temozolamide-induced DNA methylation. The MGMT inhibitor O6-benzylguanine (BG) has demonstrated efficacy in depleting MGMT and maximizing tumor response in early phase clinical trials. However, because MGMT expression is also low in hematopoietic cells, this has resulted in unacceptable bone marrow toxicity, and this approach has been abandoned. We hypothesized that chemoprotection of hematopoieticprogenitor cells (HPC) with an MGMT mutant (MGMT-P140K) characterized by normal methyltransferase activity coupled with low affinity for BG, would maximize anti-tumor response while enabling patients to tolerate TMZ & BG dose escalation with minimal toxicity. We thus performed a phase I trial to test this hypothesis. METHODS: We treated 7 consecutive patients with newly diagnosed GBM with standard surgery and radiation, followed by transplantation with autologous CD34+hematopoetic progenitor cells engineered to express MGMT-P140K using a lentiviral vector in three arms. To assess chemo-protection, patients' blood counts and transgene marking were monitored during the treatment as was tumor growth and survival. RESULTS: The viral transduction rates were 2.5-75% and were clearly improved in the third arm with intra-patient dose escalation. P140K-MGMT gene markings in peripheral blood and bone marrow cells increased 3-26-fold with only mild-moderate (Grade 2-3) mylosuppression consistent with chemo-selection and chemo-protection as hypothesized. Survival ranged from 20-36 months which exceeded their RPA predicted survival by 1.9-3.2 fold suggesting clinical benefit (mean 2.0). Viral insertion site analysis failed to demonstrate evidence of clonal dominance. CONCLUSION: These preliminary result demonstrates that this chemoprotection strategy is tolerable, safe, and facilitates TMZ & BG dose escalation resulting in increased survival in a small cohort of selected patients. A phase II study is planned.
INTRODUCTION: Glioblastoma (GBM) is the most common malignant brain tumor with a median survival of 15 months despite surgery and aggressive radio-chemotherapy. The most important mechanism of TMZ resistance is the O6-methylguanine-DNA methyltransferase (MGMT) gene which repairs temozolamide-induced DNA methylation. The MGMT inhibitor O6-benzylguanine (BG) has demonstrated efficacy in depleting MGMT and maximizing tumor response in early phase clinical trials. However, because MGMT expression is also low in hematopoietic cells, this has resulted in unacceptable bone marrow toxicity, and this approach has been abandoned. We hypothesized that chemoprotection of hematopoieticprogenitor cells (HPC) with an MGMT mutant (MGMT-P140K) characterized by normal methyltransferase activity coupled with low affinity for BG, would maximize anti-tumor response while enabling patients to tolerate TMZ & BG dose escalation with minimal toxicity. We thus performed a phase I trial to test this hypothesis. METHODS: We treated 7 consecutive patients with newly diagnosed GBM with standard surgery and radiation, followed by transplantation with autologous CD34+hematopoetic progenitor cells engineered to express MGMT-P140K using a lentiviral vector in three arms. To assess chemo-protection, patients' blood counts and transgene marking were monitored during the treatment as was tumor growth and survival. RESULTS: The viral transduction rates were 2.5-75% and were clearly improved in the third arm with intra-patient dose escalation. P140K-MGMT gene markings in peripheral blood and bone marrow cells increased 3-26-fold with only mild-moderate (Grade 2-3) mylosuppression consistent with chemo-selection and chemo-protection as hypothesized. Survival ranged from 20-36 months which exceeded their RPA predicted survival by 1.9-3.2 fold suggesting clinical benefit (mean 2.0). Viral insertion site analysis failed to demonstrate evidence of clonal dominance. CONCLUSION: These preliminary result demonstrates that this chemoprotection strategy is tolerable, safe, and facilitates TMZ & BG dose escalation resulting in increased survival in a small cohort of selected patients. A phase II study is planned. LGGs cause difficulties in assigning therapies. In this report, we compile findings relating to LGG genetics and treatment options in order to create a coherent summary for referential use. METHODS: We compiled 70 articles from the past ten years that cover a broad range of topics pertaining to LGGs, including molecular, genetic, epigenetic, morphological, and other diagnostic factors, as well as prognosis and treatment options. RESULTS: Molecular basis and histology of the tumor must be addressed for proper treatment. The 1p/19q co-deletion indicator has been considered the gold standard of glioma diagnosis and prognosis, but oft-sighted mutations in the IDH1 and IDH2 genes have given rise to three subgroups of 1p/19q co-deleted tumors, each associated with specific patterns of glial cells. Other molecular markers and microRNA expression patterns have been studied for possible diagnostic/prognostic methods. Microsurgical resection is the singular treatment with highest overall survival (OS) and quality of life (QOL). Total gross resection is optimal, with patients having a 5-year OS of 100% with 90% tumor resection. Low doses of radiation are as effective as high doses and are better tolerated. Additionally, radiation followed by PCV chemotherapy caused major increases in OS. Temozolomide also offers a favorable toxicity profile and QOL; additionally, seizure reduction is an early and consistent prognostic marker for survival after treatment with Temozolomide. CONCLUSIONS: The "wait and see" approach for treatment is no longer the standard for LGGs. Immediate treatment after diagnosis is recommended. Gross total resection (if achievable) is the most favorable treatment, with the highest OS and QOL. The use of chemotherapy and radiotherapy is recommended. Histological background and genetic markers are vital for determining a treatment plan. LGG patients (years 2000-2013) in a single institution pathology database was performed. We identified 51 patients with LGG that were treated with upfront RT. Characteristics including age, gender, high-risk features (age≥40, tumor size>6 cm, tumor crossing midline, neurologic deficit at diagnosis), and use of RT and chemotherapy were determined. 16 patients received CRT (14 of which received temozolomide), and 35 patients received RT alone (median dose 54Gy). 46 patients had high risk LGG (15/16 receiving CRT, 31/35 receiving RT alone). Survival and progression free survival, based on serial imaging and electronic medical records, were assessed. Kaplan Meier analysis was used to assess time to events, and log rank test was used to compare patients who received RT to those receiving CRT. RESULTS: 5-year progression free survival for patients receiving CRT was 72% versus 54% in patients receiving radiation alone (p=0.03). 5-year overall survival for patients receiving CRT was 93% versus 79% in patients receiving radiation alone (p=0.04). Cox Proportional Hazards analysis revealed that patients with biopsy alone (HR=7.24, p=0.03), RT alone (HR=4.08, p=0.04) and having neurologic deficit at presentation (HR=4.57, p<0.01) had increased risk of death. Cox Proportional Hazards analysis showed that use of upfront RT was the only factor that increased the risk of earlier recurrence (HR=2.72, p=0.03). CONCLUSION: Use of upfront predominantly temozolomide-based CRT had overall survival benefit over RT alone in a population of WHO grade II gliomas treated. CRT was the only factor in this study that predicted for improved time to recurrence.
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